SVB Wealth’s Royalty Pharma RPRX Stock Holding History

SVB Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,917	Closed	-$90.8K	–	1391
2025 Q1	$90.8K	Buy	+2,917	New	+$92.5K	﹤0.01%	423

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

SVB Wealth's RPRX Position: Q2 2025 in Review

SVB Wealth sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 2,917 shares — an estimated $90.8K sold.

SVB Wealth first reported a position in RPRX in Q1 2025 and held it in 1 quarter. The position peaked at $90.8K in Q1 2025. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

SVB Wealth reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 2,917 Royalty Pharma shares in Q2 2025, an estimated $90.8K.
SVB Wealth first reported a position in Royalty Pharma in Q1 2025 and held it in 1 quarter.
SVB Wealth's Royalty Pharma position peaked at $90.8K in Q1 2025.
455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.